REPATHA PUSHTRONEX (evolocumab)

420 mg/3.5 mL subcutaneous wearable injector

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or upper arm

Atherosclerotic cardiovascular disease

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route every 4 weeks via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or upper arm

Heterozygous familial hypercholesterolemia

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route every 4 weeks via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or upper arm

Homozygous familial hypercholesterolemia

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route every 4 weeks via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or upper arm

Hypercholesterolemia

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route every 4 weeks via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or upper arm

Myocardial infarction prevention

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route every 4 weeks via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or upper arm

Prevention of cerebrovascular accident

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route every 4 weeks via on-body infusor in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month in the abdomen, thigh, or outer area of upper arm

• Inject 3.5 milliliters (420 mg) over 9 minute(s) by subcutaneous route once a month via on-body infusor in the abdomen, thigh, or upper arm